{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:29:52Z","timestamp":1792430992507,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.nmni.2026.101747","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:46:02Z","timestamp":1774770362000},"page":"101747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Antimicrobial resistance crisis in STIs: Gonorrhea and M. genitalium on the brink of untreatability"],"prefix":"10.1016","volume":"71","author":[{"given":"Nafiseh","family":"Ghodsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roghayeh","family":"Arezoomand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2532-8198","authenticated-orcid":false,"given":"Amir","family":"Azimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.nmni.2026.101747_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/infdis\/jiad047","article-title":"The estimated lifetime quality-adjusted life-years lost due to chlamydia, gonorrhea, and trichomoniasis in the United States in 2018","volume":"227","author":"Li","year":"2023","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/sextrans-2019-053999","article-title":"Pregnancy and fertility-related adverse outcomes associated with Chlamydia trachomatis infection: a global systematic review and meta-analysis","volume":"96","author":"Tang","year":"2020","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.nmni.2026.101747_bib3","series-title":"Gonococcal infections in the adult","author":"Hook","year":"1990"},{"key":"10.1016\/j.nmni.2026.101747_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2471\/BLT.12.107623","article-title":"Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis","volume":"91","author":"Gomez","year":"2013","journal-title":"Bull World Health Organ"},{"issue":"10","key":"10.1016\/j.nmni.2026.101747_bib5","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1097\/OLQ.0000000000001403","article-title":"Risk of HIV acquisition among men who have sex with men infected with bacterial sexually transmitted infections: a systematic review and meta-analysis","volume":"48","author":"Malekinejad","year":"2021","journal-title":"Sex Transm Dis"},{"issue":"15","key":"10.1016\/j.nmni.2026.101747_bib6","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1017\/S0950268816001679","article-title":"Examining the role of socioeconomic deprivation in ethnic differences in sexually transmitted infection diagnosis rates in England: evidence from surveillance data","volume":"144","author":"Furegato","year":"2016","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.nmni.2026.101747_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1600-0412.2000.079002123.x","article-title":"The frequency of salpingitis and ectopic pregnancy as epidemiologic markers of Chlamydia trachomatis","volume":"79","author":"Bjartling","year":"2000","journal-title":"Acta Obstet Gynecol Scand: Orig Article"},{"issue":"11","key":"10.1016\/j.nmni.2026.101747_bib8","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"issue":"11","key":"10.1016\/j.nmni.2026.101747_bib9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.nmni.2026.101747_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/sextrans-2017-053384","article-title":"Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis","volume":"94","author":"Baumann","year":"2018","journal-title":"Sex Transm Infect"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12864-020-6511-6","article-title":"Genomic evolution of Neisseria gonorrhoeae since the preantibiotic era (1928\u20132013): antimicrobial use\/misuse selects for resistance and drives evolution","volume":"21","author":"Golparian","year":"2020","journal-title":"BMC Genom"},{"issue":"3","key":"10.1016\/j.nmni.2026.101747_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14737159.2022.2015329","article-title":"Antimicrobial resistance prediction in Neisseria gonorrhoeae: current status and future prospects","volume":"22","author":"Golparian","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"issue":"7","key":"10.1016\/j.nmni.2026.101747_bib15","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.nmni.2026.101747_bib16","first-page":"168","article-title":"2012 European guideline on the diagnosis and treatment of gonorrhoea in adults","volume":"101","author":"Bignell","year":"2014","journal-title":"Dermatol Rev\/Przeglad Dermatologiczny"},{"issue":"25","key":"10.1016\/j.nmni.2026.101747_bib17","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1512757","article-title":"Failure of dual antimicrobial therapy in treatment of gonorrhea","volume":"374","author":"Fifer","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.nmni.2026.101747_bib18","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1128\/AAC.00504-16","article-title":"New ceftriaxone-and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan","volume":"60","author":"Nakayama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/22221751.2021.2011618","article-title":"Dissemination and genome analysis of high-level ceftriaxone-resistant penA 60.001 Neisseria gonorrhoeae strains from the Guangdong gonococcal antibiotics susceptibility programme (GD-GASP), 2016\u20132019","volume":"11","author":"Lin","year":"2022","journal-title":"Emerg Microb Infect"},{"issue":"7","key":"10.1016\/j.nmni.2026.101747_bib20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/jac\/dkz129","article-title":"Clonal expansion and spread of the ceftriaxone-resistant Neisseria gonorrhoeae strain FC428, identified in Japan in 2015, and closely related isolates","volume":"74","author":"Lee","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.nmni.2026.101747_bib21","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S1473-3099(23)00479-6","article-title":"The enhanced gonococcal surveillance programme, Cambodia","volume":"23","author":"Ouk","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.nmni.2026.101747_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1473-3099(20)30055-4","article-title":"Lessons learnt from ceftriaxone-resistant gonorrhoea in the UK and Australia","volume":"20","author":"Fifer","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.nmni.2026.101747_bib23","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"issue":"46","key":"10.1016\/j.nmni.2026.101747_bib24","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200803","article-title":"Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022","volume":"27","author":"Day","year":"2022","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/IM9.0000000000000113","article-title":"Global transmission of the penA allele 60.001\u2013containing high-level ceftriaxone-resistant gonococcal FC428 clone and antimicrobial therapy of associated cases: a review","volume":"5","author":"van der Veen","year":"2023","journal-title":"Infectious Microbes Dis"},{"issue":"10","key":"10.1016\/j.nmni.2026.101747_bib26","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.10.2300125","article-title":"Multidrug-resistant Neisseria gonorrhoeae isolate SE690: Mosaic penA-60.001 gene causing ceftriaxone resistance internationally has spread to the more antimicrobial-susceptible genomic lineage, Sweden, September 2022","volume":"28","author":"Golparian","year":"2023","journal-title":"Euro Surveill"},{"issue":"7","key":"10.1016\/j.nmni.2026.101747_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.nmni.2026.101747_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002344","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action","volume":"14","author":"Wi","year":"2017","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.nmni.2026.101747_bib29","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1086\/593188","article-title":"Azithromycin treatment failure in mycoplasma genitalium\u2013positive patients with nongonococcal urethritis is associated with induced macrolide resistance","volume":"47","author":"Jensen","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.nmni.2026.101747_bib30","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/AAC.02411-14","article-title":"In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and-susceptible Mycoplasma genitalium strains","volume":"58","author":"Jensen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.nmni.2026.101747_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/ciy477","article-title":"Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation","volume":"68","author":"Read","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/cid\/ciz294","article-title":"Mycoplasma genitalium in symptomatic male urethritis: macrolide use is associated with increased resistance","volume":"70","author":"Li","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.nmni.2026.101747_bib33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1089\/mdr.2020.0490","article-title":"Is there a resistance threshold for macrolide consumption? Positive evidence from an ecological analysis of resistance data from Streptococcus pneumoniae, Treponema pallidum, and Mycoplasma genitalium","volume":"27","author":"Kenyon","year":"2021","journal-title":"Microb Drug Resist"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/sextrans-2016-053060","article-title":"Which azithromycin regimen should be used for treating mycoplasma genitalium? A meta-analysis","volume":"94","author":"Horner","year":"2018","journal-title":"Sex Transm Infect"},{"issue":"3","key":"10.1016\/j.nmni.2026.101747_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/cid\/ciw719","article-title":"Azithromycin 1.5 g over 5 days compared to 1g single dose in urethral mycoplasma genitalium: impact on treatment outcome and resistance","volume":"64","author":"Read","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.nmni.2026.101747_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2010.05.011","article-title":"Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance","volume":"36","author":"Shimada","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.nmni.2026.101747_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jiac.2021.11.011","article-title":"Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary Mycoplasma genitalium strains","volume":"28","author":"Hamasuna","year":"2022","journal-title":"J Infect Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00278-22","article-title":"parC variants in mycoplasma genitalium: trends over time and association with moxifloxacin failure","volume":"66","author":"Murray","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.nmni.2026.101747_bib39","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1473-3099(21)00629-0","article-title":"Individualised treatment of Mycoplasma genitalium infection\u2014incorporation of fluoroquinolone resistance testing into clinical care","volume":"22","author":"Sweeney","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.nmni.2026.101747_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3201\/eid2402.170902","article-title":"Use of pristinamycin for macrolide-resistant Mycoplasma genitalium infection","volume":"24","author":"Read","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.nmni.2026.101747_bib41","series-title":"Open forum infectious diseases","article-title":"Nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance","author":"Doyle","year":"2020"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib42","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/jac\/dky022","article-title":"In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains","volume":"73","author":"Dami\u00e3o Gouveia","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib43","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1080\/22221751.2020.1775498","article-title":"In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and-susceptible Mycoplasma genitalium","volume":"9","author":"Jensen","year":"2020","journal-title":"Emerg Microb Infect"},{"issue":"11","key":"10.1016\/j.nmni.2026.101747_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00819-21","article-title":"Azithromycin and doxycycline resistance profiles of US Mycoplasma genitalium strains and their association with treatment outcomes","volume":"59","author":"Wood","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00243-22","article-title":"Impact of 16S rRNA single nucleotide polymorphisms on Mycoplasma genitalium organism load with doxycycline treatment","volume":"66","author":"Chua","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib46","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/jac\/dkab016","article-title":"Identification of 16S rRNA mutations in Mycoplasma genitalium potentially associated with tetracycline resistance in vivo but not selected in vitro in M. genitalium and Chlamydia trachomatis","volume":"76","author":"Le Roy","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.nmni.2026.101747_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00698-20","article-title":"In vitro activities of eravacycline and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"64","author":"Waites","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.nmni.2026.101747_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01886-19","article-title":"Single-locus-sequence-based typing of the mgpB gene reveals transmission dynamics in Mycoplasma genitalium","volume":"58","author":"Fern\u00e1ndez-Huerta","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib49","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1186\/s12864-017-4399-6","article-title":"Mycoplasma genitalium: whole genome sequence analysis, recombination and population structure","volume":"18","author":"Fookes","year":"2017","journal-title":"BMC Genom"},{"issue":"3","key":"10.1016\/j.nmni.2026.101747_bib50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","article-title":"Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial","volume":"18","author":"Molina","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"10.1016\/j.nmni.2026.101747_bib51","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","article-title":"Postexposure doxycycline to prevent bacterial sexually transmitted infections","volume":"388","author":"Luetkemeyer","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.nmni.2026.101747_bib52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41585-023-00788-1","article-title":"Doxycycline-PEP\u2014Novel and promising but needs monitoring","volume":"20","author":"Unemo","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"7","key":"10.1016\/j.nmni.2026.101747_bib53","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/jac\/dkad129","article-title":"Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections","volume":"78","author":"Kong","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nmni.2026.101747_bib54","article-title":"Resistance and prevalence implications of doxycycline post-exposure prophylaxis for gonorrhea prevention in men who have sex with men: a modeling study","author":"Reichert","year":"2023","journal-title":"medRxiv"},{"issue":"8","key":"10.1016\/j.nmni.2026.101747_bib55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(19)30116-1","article-title":"Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study","volume":"46","author":"Hook","year":"2019","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jac\/dkac366","article-title":"GyrB in silico mining in 27 151 global gonococcal genomes from 1928\u20132021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility","volume":"78","author":"Golparian","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.nmni.2026.101747_bib58","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.nmni.2026.101747_bib59","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.nmni.2026.101747_bib60","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of neisseria gonorrheae, including multi-drug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"12","key":"10.1016\/j.nmni.2026.101747_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00362-22","article-title":"Potent in vitro and ex vivo anti-gonococcal activity of the RpoB inhibitor corallopyronin A","volume":"7","author":"Edwards","year":"2022","journal-title":"mSphere"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/apm.12777","article-title":"In vitro activity and time\u2010kill curve analysis of sitafloxacin against a global panel of antimicrobial\u2010resistant and multidrug\u2010resistant Neisseria gonorrhoeae isolates","volume":"126","author":"J\u00f6nsson","year":"2018","journal-title":"Apmis"},{"issue":"5","key":"10.1016\/j.nmni.2026.101747_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02380-17","article-title":"In vitro activity of lefamulin against sexually transmitted bacterial pathogens","volume":"62","author":"Paukner","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.nmni.2026.101747_bib65","first-page":"208","article-title":"Novel use of oral chloramphenicol for treatment-resistant Mycoplasma genitalium","volume":"99","author":"Goodfellow","year":"2023","journal-title":"Sex Transm Infect"},{"issue":"9","key":"10.1016\/j.nmni.2026.101747_bib66","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1128\/AAC.00309-10","article-title":"High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes","volume":"54","author":"Chisholm","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.nmni.2026.101747_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107101","article-title":"penA profile of Neisseria gonorrhoeae in Guangdong, China: novel penA alleles are related to decreased susceptibility to ceftriaxone or cefixime","volume":"63","author":"Liao","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.nmni.2026.101747_bib68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12866-019-1439-1","article-title":"gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya","volume":"19","author":"Kivata","year":"2019","journal-title":"BMC Microbiol"},{"issue":"4","key":"10.1016\/j.nmni.2026.101747_bib69","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkp505","article-title":"Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone","volume":"65","author":"Lee","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205229752600051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205229752600051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:57:08Z","timestamp":1779717428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205229752600051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":69,"alternative-id":["S205229752600051X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101747","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial resistance crisis in STIs: Gonorrhea and M. genitalium on the brink of untreatability","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101747"}}